Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab
| Autor: | J. X. Lima Neto, Ana Beatriz M. L. A. Tavares, Umberto L. Fulco, Eudenilson L. Albuquerque |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
biology
Chemistry Programmed Cell Death 1 Receptor General Physics and Astronomy Interaction energy Pembrolizumab Antibodies Monoclonal Humanized Ligands Ligand (biochemistry) B7-H1 Antigen Protein Structure Tertiary Nivolumab Immune system PD-L1 Cancer cell biology.protein Cancer research Humans Thermodynamics Physical and Theoretical Chemistry Density Functional Theory Protein Binding Conjugate |
| Zdroj: | Physical Chemistry Chemical Physics. 23:21207-21217 |
| ISSN: | 1463-9084 1463-9076 |
| Popis: | We investigate the interaction between the programmed cell death protein 1 (PD-1) and the programmed cell death ligand 1 (PD-L1), as well as the immuno-oncological drugs pembrolizumab (PEM), and nivolumab (NIV), through quantum chemistry methods based on the Density Functional Theory (DFT) and the molecular fractionation with conjugate caps (MFCC) scheme, in order to map their hot-spot regions. Our results showed that the total interaction energy order of the three complexes is in good agreement with the experimental binding affinity order: PD-1/PEM > PD-1/NIV > PD-1/PD-L1. Besides, a detailed investigation revealed the energetically most relevant residue-residue pairs-interaction for each complex. Our computational results give a better understanding of the interaction mechanism between the protein PD-1 and its ligands (natural and inhibitors), unleashing the immune surveillance to destroy the cancer cells by decreasing their immune evasion. They are also an efficient alternative towards the development of new small-molecules and antibody-based drugs, pointing out to new treatments for cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|